Gensight Biologics SIGHT.PA · EUR

Its shares trade on Euronext Paris under the ticker SIGHT.PA. It has been listed since 13 July 2016. In the fiscal year to 31 December 2025, it reported revenue of €1,000 and a net loss of €12.0m. At that date it held total assets of €8.3m and shareholders' equity of −€24.9m.

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Michael WyzgaChairman of the Board€120,000
• Ms. Laurence RodriguezChief Executive Officer
• Prof. Jose-Alain SahelFounder, Director
• Ms. Connie CepkoFounder
• Dr. Serge PicaudFounder
• Dr. Botond RoskaFounder
• Dr. Luk H. VandenbergheFounder
• Mr. Jan UmiastowskiChief Financial Officer
• Mr. Julio BenedictoSenior Vice President - Strategy and Operations
• Dr. Scott JeffersChief Technology Officer
• Ms. Magali GibouVice President - Regulatory and Quality
• Ms. Marion GhibaudoChief Technical Officer - Medical Device

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.